Abstract: Compositions and methods are provided for enhancing the efficiency of gene editing by timing the expression and activity of a nuclease to correspond with availability of a repair template. Compositions and methods for temporally regulating the duration of nuclease activity, and methods of selectively preventing nuclease expression during viral vector production, are also provided.

Abstract: Compositions and methods are provided for enhancing the efficiency of gene editing by timing the expression and activity of a nuclease to correspond with availability of a repair template. Compositions and methods for temporally regulating the duration of nuclease activity, and methods of selectively preventing nuclease expression during viral vector production, are also provided.

Abstract: A method for treating acute or chronic pancreatitis in a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor.

Abstract: A method for treating an inflammatory disease of the digestive tract, for example inflammatory bowel disease, in a subject comprises administering to the subject a therapeutically effective amount of a compound selected from the group consisting of (S,S)-2- [1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylamino]-4-methylpentanoic acid and pharmaceutically acceptable salts thereof.

Abstract: A method for managing or treating an inflammatory, erosive, dyspeptic or reflux disorder of the proximal digestive tract of a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor. A therapeutic combination, useful to treat any disease or condition in which an NSAID is indicated, comprises an NSAID in an anti-inflammatory, analgesic or antipyretic effective amount and a gastroprotective agent that comprises an ACE2 inhibitor in an amount effective to protect mucosal surfaces of the proximal digestive tract from erosion or ulceration induced by the NSAID.

Abstract: A method for treating acute or chronic pancreatitis in a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor.

Abstract: A method is provided for reducing or alleviating inflammation or a pathological process associated therewith or secondary thereto in a subject having an inflammatory disease of the digestive tract. The method comprises administering to the subject an anti-inflammatorily effective amount of an ACE2 inhibitor.

Abstract: A class of carrier molecules which when covalently linked to an immunogen enhances the host's immune response to that immunogen, regardless of whether the complex of carrier and immunogen is administered parenterally, enterally, or orally to the host. Also provided are processes for production of the complexes, as well as hybrid DNA sequences encoding the complexes, recombinant DNA molecules bearing the hybrid DNA sequences, transformed hosts and vaccines comprising the complexes, and methods for production of the vaccine.

Abstract: Class of carrier molecules which when covalently linked to an immunogen enhances the host's immune response to that immunogen regardless of whether the complex of carrier and immunogen is administered parenterally, enterally, or orally to the host. In addition, processes are provided for production of the complexes, as well as hybrid DNA sequences encoding complexes, recombinant DNA molecules bearing the hybrid DNA sequences, transformant hosts and vaccines comprising the complexes as well as methods for production of the vaccine.